

The Pursuit of Reliable Infection Protection in PIDD

PLEASE JOIN US

Wednesday, March 24th, 2021

Speaker: Joshua S. Jacobs, MD
Medical Director
Allergy and Asthma Clinical Research, Inc.
Walnut Creek, CA

Location: Virtual

Time: 12:15pm PT

Hosted by: Rikki Mensch
Email: rikki.mensch@grifols.com
Phone: 720-643-9342

REGISTRATION INFORMATION

To register for this program, please fax the accompanying Registration Form to **770-677-5524**, or register online at <https://www.pathlms.com/grixem20/events>. To register by phone, or if you have any questions regarding this program, please contact your local Sales Representative or call **919-846-1397**.

Sales Representative: Rikki Mensch
Email/Phone: rikki.mensch@grifols.com / 720-643-9342

Grifols will disclose any fees and/or expenses provided to covered recipients in accordance with applicable federal and state laws. In accordance with the Pharmaceutical Research and Manufacturers of America (PhRMA) Code on Interactions with Healthcare Professionals, attendance at this educational program is limited to healthcare professionals. Accordingly, attendance by guests or spouses cannot be accommodated. Minnesota healthcare practitioners are limited by government regulations to a \$50 "gift" cap per year. Any potential overage must be disclosed to the state of Minnesota by Grifols. Vermont healthcare practitioners are limited by government regulations from receiving "anything of value" (including food) from medical device, pharmaceutical, and biological manufacturers. Any violation must be disclosed to the state of Vermont by Grifols. New Jersey prescribers are limited by government regulations to specific dollar amounts for breakfast, lunch, and dinner when associated with "promotional activity." Meals provided incident to an "education event" are not subject to specified meal limits. All prescribers with active New Jersey licenses practicing in New Jersey or treating New Jersey patients are subject to the gift ban. Federal employees are prohibited by government regulations from receiving gifts (including meals) valued in excess of \$20 on any occasion and more than \$50 in a calendar year from any single contractor, except in connection with "widely attended gatherings" or incident to a society or membership unrelated to their government employment. In order to ensure compliance with these regulations, federal employees must preregister for this program if the program is not in conjunction with a society meeting. Privacy Policy: The information requested on this form is being collected to ensure compliance with any applicable federal and state reporting requirements and will not be distributed to other parties for solicitation purposes.

5818MR2421W

GRIFOLS

Please see Important Safety Information on page 3 and refer to accompanying full Prescribing Information for XEMBIFY.

REGISTRATION FORM

REGISTRATION INFORMATION

To register for this program, please fax the accompanying Registration Form to **770-677-5524**, or register online at **<https://www.pathlms.com/grixem20/events>**.

To register by phone, or if you have any questions regarding this program, please contact your local Sales Representative or call **919-846-1397**.

Sales Representative: **Rikki Mensch**

Email/Phone: **rikki.mensch@grifols.com / 720-643-9342**

PLEASE be sure to complete each field below.

Please provide your full legal name. For primary business address, please provide a street address, not a PO Box number.

Full Name _____

Professional Designation _____

Specialty _____

Practice/Affiliation _____

NPI # _____

Address _____

City _____

State _____ ZIP _____

Phone _____ Ext. _____

Email _____

5818MR2421W

IMPORTANT SAFETY INFORMATION

Indication

XEMBIFY® (immune globulin subcutaneous human-klhw) is a 20% immune globulin indicated for treatment of primary humoral immunodeficiency disease (PIDD) in patients 2 years of age and older. XEMBIFY is for subcutaneous administration only.

Important Safety Information

WARNING: THROMBOSIS

- **Thrombosis may occur with immune globulin products, including XEMBIFY. Risk factors may include: advanced age, prolonged immobilization, estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors**
- **For patients at risk of thrombosis, administer XEMBIFY at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity**

Contraindications

XEMBIFY is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the administration of human immune globulin. It is contraindicated in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.

Warnings and Precautions

Hypersensitivity. Severe hypersensitivity reactions may occur with immune globulin products, including XEMBIFY. In case of hypersensitivity, discontinue infusion immediately and institute appropriate treatment. XEMBIFY contains IgA. Patients with known antibodies to IgA may have a greater risk of developing potentially severe hypersensitivity and anaphylactic reactions.

Thrombosis. Thrombosis may occur following treatment with immune globulin products, including XEMBIFY. Thrombosis may occur in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Aseptic meningitis syndrome (AMS). AMS may occur with human immune globulin treatment, including XEMBIFY. Conduct a thorough neurological exam on patients exhibiting signs and symptoms to rule out other causes of meningitis. Discontinuation of treatment has resulted in remission within several days without sequelae.

Renal dysfunction/failure. Acute renal dysfunction/failure, acute tubular necrosis,

proximal tubular nephropathy, osmotic nephrosis, and death may occur with use of human immune globulin products, especially those containing sucrose. XEMBIFY does not contain sucrose. Ensure patients are not volume-depleted prior to starting infusion. In patients at risk due to preexisting renal insufficiency or predisposition to acute renal failure, assess renal function prior to the initial infusion of XEMBIFY and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuation.

Hemolysis. XEMBIFY may contain blood group antibodies that may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for clinical signs and symptoms of hemolysis. If signs and symptoms are present after infusion, perform confirmatory lab testing.

Transfusion-related acute lung injury (TRALI).

Noncardiogenic pulmonary edema may occur in patients following treatment with immune globulin products, including XEMBIFY. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of antineutrophil and anti-HLA antibodies in both the product and patient serum. TRALI may be managed using oxygen therapy with adequate ventilatory support.

Transmissible infectious agents. Because XEMBIFY is made from human blood, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD, or CJD have ever been associated with the use of XEMBIFY.

Interference with lab tests. After infusion of XEMBIFY, passively transferred antibodies in the patient's blood may yield positive serological testing results, with the potential for misleading interpretation.

Adverse Reactions

The most common adverse reactions in ≥5% of subjects in the clinical trial were local adverse reactions, including infusion-site erythema (redness), infusion-site pain, infusion-site swelling (puffiness), infusion-site bruising, infusion-site nodule, infusion-site pruritus (itching), infusion-site induration (firmness), infusion-site scab, infusion-site edema, and systemic reactions including cough and diarrhea.

Drug Interactions

Passive transfer of antibodies may transiently interfere with the immune responses to live attenuated virus vaccines (eg, measles, mumps, rubella, and varicella).

Please see accompanying full Prescribing Information for XEMBIFY.